Skip to main content
Top
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Correction

Correction to: Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study

Authors: Jian-jun Li, Jie Luo, Jing-ning Lu, Xiao-na Liang, Yi-huan Luo, Yong-ru Liu, Jie Yang, Hua Ding, Gui-hui Qin, Li-hua Yang, Yi-wu Dang, Hong Yang, Gang Chen

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Excerpt

Following the publication of the original article [1], the authors reported that they had supplied the incorrect figure 6 for publication. The correct Fig. 6 is given in this correction article. The results and conclusions described therein are not affected by these corrections. The authors sincerely apologize for the error. This has now been included in this correction article.
Metadata
Title
Correction to: Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study
Authors
Jian-jun Li
Jie Luo
Jing-ning Lu
Xiao-na Liang
Yi-huan Luo
Yong-ru Liu
Jie Yang
Hua Ding
Gui-hui Qin
Li-hua Yang
Yi-wu Dang
Hong Yang
Gang Chen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-1138-x

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine